Bexsero, meningitis B vaccine vaccination campaign results released
Novartis has announced the initial results of a large-scale vaccination campaign with Bexsero® (Meningococcal Group B Vaccine [rDNA, component, adsorbed]) to help protect against meningitis B within the Saguenay-Lac-Saint-Jean More...
Novartis seeks FDA approval for meningitis B vaccine, Bexsero
Basel, June 17, 2014 – Novartis announced today the submission of a Biologic License Application (BLA) to the US Food and Drug Administration (FDA) for marketing approval for the use of Bexsero® (Multicomponent More...
Bexsero, meningitis B vaccine, receives FDA Breakthrough Therapy designation
PRESS RELEASE Novartis announced today that Bexsero® (Meningococcal Group B Vaccine [rDNA, component, adsorbed]) has received a Breakthrough Therapy designation from the United States Food and Drug Administration More...
British health officials recommend Bexsero as part of routine childhood immunization schedule
The Joint Committee on Vaccination and Immunisation (JCVI) in Great Britain has recommended the inclusion of the meningitis B vaccine, Bexsero, to be part of the routine childhood immunization schedule, according More...
UC Santa Barbara will be offering the meningitis B vaccine, Bexsero, starting Feb. 24
In a follow-up to a story one month ago, The University of California, Santa Barbara (UCSB), who has experienced four cases of meningococcal meningitis group B during a three week time frame in Nov. 2013, will More...
The Top 10 Infectious Disease and Outbreak News stories of 2013
2013 was a year full of impactful infectious disease stories with outbreaks of diseases not before seen in humans, diseases seen in new parts of the planet and miracle stories of survivors. Drugs not approved in More...
Princeton vaccinates 4,361 with Bexsero with one clinic day left
Princeton University said Wednesday that more than 4,300 people received the first dose of the two-dose series of the meningococcal serogroup B vaccine after three days of clinic operations. Neisseria meningitidisImage/CDC As More...
Princeton vaccinates hundreds on first day with meningitis B vaccine, Bexsero
According to Princeton University, as of 4:30 p.m today, 1,261 individuals were vaccinated to help protect against meningococcal disease caused by serogroup B bacteria. Neisseria meningitidisImage/CDC In a More...
CDC expert: Use of unlicensed vaccine, Bexsero, ‘highly unusual’
During a telebriefing yesterday with CDC pediatrician and meningitis expert, Dr Amanda Cohn, a couple of key questions were answered concerning the Novartis meningitis vaccine, Bexsero. Neisseria meningitidisImage/CDC When More...
What is Bexsero? How common is meningococcal disease serogroup B?
With the eighth case of meningococcal meningitis confirmed at Princeton University yesterday, and at least seven confirmed as Neisseria meningitis serotype B (MenB) with the most recent still pending, health officials More...
Princeton University reports 8th meningitis case
A Princeton University student is receiving treatment after she was diagnosed with meningitis yesterday. The student developed symptoms Wednesday night and went to the University’s McCosh Health Center, from More...
Princeton hopes to make Bexsero available for students in December
In a follow-up to an earlier story, Princeton University announced today via email that they will be receiving the EU/Australia approved meningococcal meningitis vaccine, Bexsero, to offer to immunize students against More...
Bexsero, first Meningitis B vaccine, receives European Commission approval
Photo/CDC/ Debora Cartagena Switzerland-based pharmaceutical and health care company, Novartis announced this week that it’s Meningitis B vaccine, Bexsero, has received approval from the European Commission More...
